Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Xeris Pharmaceuticals (Nasdaq: XERS) announced an amendment to its loan agreement with Oxford Finance and Silicon Valley Bank, extending interest-only payments for up to 12 months. This allows the company to defer principal payments of $17.4 million initially due between January and December 2022 to January 2023. The final maturity date of the debt facility is set for June 1, 2024. CEO Paul R. Edick emphasized the flexibility this provides to conserve cash while advancing Gvoke's sales, which treats hypoglycemia.
Xeris Pharmaceuticals (Nasdaq: XERS) has received approval from the UK’s Medicines and Healthcare Regulatory Agency for Ogluo® (glucagon) injection, indicated for treating severe hypoglycemia in patients aged 2 and above with diabetes. Previously, Ogluo was approved by the European Commission in February 2021. The marketing authorization is recognized in the UK and 27 EU countries. Xeris is actively seeking commercialization partners, aiming for a fourth quarter 2021 launch in select EU regions. Gvoke, a similar product, was FDA-approved in September 2019.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 15,250 restricted stock units to 10 new employees on March 31, 2021. This action was made under Xeris' Inducement Equity Plan, which incentivizes new hires with equity awards. The stock options will vest over four years, with specific vesting schedules tied to continued employment. Xeris specializes in ready-to-use injectable and infusible drug formulations, aimed at improving patient and healthcare experiences.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced a registered direct offering of 6,553,398 shares at $4.12 each, securing gross proceeds of $27 million. The offering, managed without underwriters, is expected to close on March 15, 2021. Proceeds will fund working capital and general corporate purposes, detailed in a forthcoming prospectus supplement. This offering is part of a shelf registration declared effective in August 2019 by the SEC. Xeris focuses on creating ready-to-use injectable therapies leveraging advanced formulation technologies.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its fourth quarter and full-year 2020 financial results, highlighting continuous growth in Gvoke prescriptions, up 11% quarter-over-quarter and 350% year-over-year. The company secured a positive opinion from the EMA for Ogluo, with expectations for a Q4 2021 launch in select EU countries. Xeris also converted $39.1 million of convertible notes into shares, improving its cash position to $133.8 million. However, the net loss for Q4 2020 was $21.9 million, a decrease from $33.1 million in Q4 2019.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its fourth quarter and full-year 2020 financial results on March 9, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET that same day to discuss the results. Xeris specializes in developing ready-to-use injectable and infusible drug formulations, leveraging its proprietary XeriSol™ and XeriJect™ technologies. These innovations aim to simplify medication administration, enhance stability, and reduce costs. For more information, visit www.xerispharma.com.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced on February 24, 2021, that its Compensation Committee granted stock options for 5,000 shares and restricted stock units for 9,500 shares to three new employees under its Inducement Equity Plan. This plan incentivizes new hires by offering equity awards, which are subject to conditions like continued employment. The options will vest over four years, and the company aims to simplify administering critical therapies through innovative room-temperature stable formulations, enhancing patient and healthcare experience.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present at several investor conferences in February and March 2021. The conferences include the SVB Leerink Annual Global Healthcare Conference on February 26 at 10:40 am ET, the HC Wainwright Global Life Sciences Conference on-demand starting March 9, and the Oppenheimer 31st Annual Healthcare Conference on March 16 at 11:20 am ET. Xeris specializes in ready-to-use injectable therapies, focusing on simplifying medication administration and enhancing patient experience.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) has received European Commission approval for Ogluo™ (glucagon) injection, aimed at treating severe hypoglycemia in diabetes patients aged 2 years and above. This marketing authorization covers all 27 EU countries, along with Iceland, Norway, and Liechtenstein. Xeris plans to launch Ogluo later this year, while also seeking commercialization partnerships to expand availability. The approval stems from a Phase 3 study showing comparable efficacy to Novo Nordisk’s GlucaGen HypoKit, with no major safety concerns noted.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 16,000 non-qualified stock options to 38 new employees as part of its Inducement Equity Plan on January 27, 2021. This plan is designed to attract individuals not previously employed by Xeris, with options vesting over four years based on continued employment. Xeris specializes in developing ready-to-use injectable and infusible drug formulations through its advanced technology platforms, offering potential cost-saving and user-friendly solutions in the pharmaceutical market.